PT  - JOURNAL ARTICLE
AU  - R Hurford
AU  - PJ Tyrrell
TI  - Stroke thrombolysis: where are we and where are we going?
AID  - 10.7861/clinmedicine.13-6-s20
DP  - 2013 Dec 01
TA  - Clinical Medicine
PG  - s20--s23
VI  - 13
IP  - Suppl 6
4099  - http://www.rcpjournals.org/content/13/Suppl_6/s20.short
4100  - http://www.rcpjournals.org/content/13/Suppl_6/s20.full
SO  - Clin Med2013 Dec 01; 13
AB  - Stroke is an important cause of death and disability throughout the world. Most strokes are ischaemic, caused by thrombotic or embolic occlusion of blood vessels. The advent of thrombolysis for acute ischaemic stroke has revolutionised the treatment of acute stroke in the developed world. The benefit of thrombolysis in acute stroke is very time-dependent, with the greatest benefit achieved when administered within 90 minutes of ictus, but trials demonstrating some benefit up to 4.5, and possibly 6 hours. This has revolutionised stroke treatment, with redesign of clinical pathways to try to ensure patients with suspected stroke reach a hospital with a thrombolysis service as quickly as possible. Clinical stroke services need to ensure that all acute stroke patients can be scanned, treated and admitted to stroke units without delay. Future research needs to address the prevention and better management of complications, such as secondary intracerebral haemorrhage and angioedema. In addition, the evidence base for direct intra-arterial intervention such as thrombectomy needs to be established.